Please wait while we load the requested 10-Q report or click the link below:
Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones
Part I of Adaptive RENEW Phase 3 Clinical Trial in Dry Eye Disease on Track for Completion in Fourth Quarter 2019
Adaptive GUARD Phase 3 Clinical Trial of ADX-2191 in Proliferative Vitreoretinopathy to Initiate in Fourth Quarter 2019
Initiation of INVIGORATE Phase 3 Clinical Trial of Reproxalap in Allergic Conjunctivitis Planned for First Half 2020
Phase 1 Clinical Trial of Novel, Orally Administered RASP Inhibitor ADX-629 Initiated
Management to Host Conference Call at 8:00 a.m. ET today
LEXINGTON, Mass., November 7, 2019 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2019. In addition, the company updated investors on anticipated clinical milestones.
Aldeyra continued to make significant progress during the quarter in advancing our immunology platform toward the goal of reducing the burden of disease and helping patients lead healthier lives, said Aldeyra President and CEO Todd C. Brady, M.D., Ph.D. We have reached agreement with the U.S. Food and Drug Administration (FDA) on the primary endpoint for our pivotal INVIGORATE Phase 3 clinical trial of reproxalap in allergic conjunctivitis. In addition, this quarter we expect to complete Part 1 of our adaptive RENEW Phase 3 clinical trial of reproxalap in dry eye disease, and initiate the first part of our adaptive GUARD Phase 3 clinical trial in proliferative vitreoretinopathy, representing the expansion of our ocular program from the front of the eye to the retina.
The following information was filed by Aldeyra Therapeutics, Inc. (ALDX) on Thursday, November 7, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aldeyra Therapeutics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Aldeyra Therapeutics, Inc..